昊海生物科技(06826.HK)業績快報：2021年度淨利潤升53.19%至3.52億元
格隆匯2月27日丨昊海生物科技(06826.HK)發佈2021年度業績快報，實現營業收入17.66億元(人民幣，下同)，同比增長32.57%；歸屬於母公司擁有人的淨利潤3.52億元，同比增長53.19%；歸屬於母公司擁有人的扣除非經常性損益的淨利潤3.27億元，同比增長58.38%；基本每股收益2元。
報吿期內，隨着國內新冠肺炎疫情得到有效控制，疫情對於集團經營活動的影響逐漸減弱，集團各產品線收入均實現大幅增長。報吿期內，集團毛利率與2020年相比穩中微降，主要原因系人工晶狀體產品部份型號在帶量採購區域銷售價格下降所致，另外，公司收購的歐華美科(天津)醫學科技有限公司自2021年9月開始，被納入公司合併範圍，其射頻及激光醫療美容設備和家用美容儀器等業務毛利率與集團原有業務相比較低，對集團整體毛利率水平造成一定影響。報吿期內，集團持續加大研發投入，多個眼科和醫美的在研項目持續進行或進入臨牀試驗階段，研發支出較2020年增長較多。
報吿期內，集團營業收入較2020年增長約32.57%，主要系2020年集團業務受到全球疫情影響較為嚴重，而報吿期內國內疫情影響已逐漸減弱，集團各項業務均已全面恢復並實現增長。
報吿期內，集團營業利潤較2020年增長約47.95%、利潤總額較2020年增長約48.81%，主要原因是集團營業收入增長及整體毛利率相對穩定帶來的毛利增長所致。同時，隨着疫情影響的減弱，各類營銷和市場活動、行政管理活動、獎金的發放等逐步恢復正常，使集團營業費用和管理費用較2020年均有所增長。另外，集團持續加大對研發投入，研發支出也較2020年增長較多。上述各項費用的增長部分抵消了集團毛利增長對報吿期內營業利潤和利潤總額的增長貢獻。
報吿期內，集團歸屬於母公司擁有人的淨利潤及歸屬於母公司擁有人的扣除非經常性損益的淨利潤較2020年分別增長約53.19%及58.38%，主要原因繫上述提到的集團營業收入及毛利增長所致。同時，報吿期內，集團非經常性損益金額與2020年基本持平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
